Inhibitory member of the apoptosis-stimulating protein of p53 (ASPP) family promotes growth and tumorigenesis in human p53-deficient prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 3, 2011, Pages 219-224

  Zhang, B ^a   Xiao, H J ^a   Chen, J ^a   Tao, X ^a   Cai, L H ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

apoptosis; iASPP; proliferation; RNA interference; tumorigenisis

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; APOPTOSIS STIMULATING PROTEIN OF P53; ONCOPROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE LEVEL; TISSUE SECTION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GENETIC VECTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; RNA INTERFERENCE; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054746852     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.25     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96 (Pubitemid 351521864)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 (Pubitemid 40372904)
3. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Bio 2007; 8: 275-283
4. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Brit J Cancer 2007; 96: 196-200 (Pubitemid 46160620)
5. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-794 (Pubitemid 33030212)
6. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004; 24: 1341-1350 (Pubitemid 38112194)
7. Bell HS, Ryan KM. iASPP inhibition. increased options in targeting the p53 family for cancer therapy. Cancer Res 2008; 68: 4959-4962
8. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162-167 (Pubitemid 36177067)
9. Gao X, Xin HM, Lu X, Zhong S, Gu SZ, Chen J. Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest 2008; 26: 878-882
10. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR, Agarwal ML. Macrophage inhibitory cytokine 1 mediates a p53- dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA 2006; 103: 16278-16283 (Pubitemid 44715187)
11. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65: 7717-7723 (Pubitemid 41297246)
12. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 2003; 63: 2905-2912 (Pubitemid 36667163)
13. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005; 11: 5084-5089 (Pubitemid 41003691)
14. Arocho A, Chen B, Ladanyi M, Pan Q. Validation of the 2-[DELTA][DELTA]Ct calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagnostic Mol Pathol 2006; 15: 56-61
15. Xu Y,Wang Z,Wang J, Li J,Wang H, YueW. Lentivirus-mediated knockdown of cyclin Y (CCNY) inhibits glioma cell proliferation. Oncol Res 2010; 18: 359-364
16. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070
17. Sinn PL, Sauter SL, McCray PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005; 12: 1089-1098 (Pubitemid 41030614)
18. Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX, Miao DS et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009; 327: 257-266
19. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumour derived p53 mutant. EMBO J 1996; 15: 827-838 (Pubitemid 26064289)
20. Bell HS, Ryan KM. iASPP inhibition. increased options in targeting the p53 family for cancer therapy. Cancer Res 2008; 68: 4959-4962